Sign up to save your podcasts
Or
Share #18 Jurjen Versluis: Transplant for high-risk MDS
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
#18 Jurjen Versluis: Transplant for high-risk MDS
Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study.
https://pubmed.ncbi.nlm.nih.gov/37607457/
ALSO AS VIDEO ON
https://youtu.be/JbHS_-2sJQc
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari
View all episodes
By The EBMT Trainee CommitteeAllogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study.
https://pubmed.ncbi.nlm.nih.gov/37607457/
ALSO AS VIDEO ON
https://youtu.be/JbHS_-2sJQc
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari